First Time Loading...

Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 21.38 USD -3.26% Market Closed
Updated: Jun 3, 2024

Intellia Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intellia Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Intellia Therapeutics Inc
NASDAQ:NTLA
Operating Income
-$892.7m
CAGR 3-Years
-81%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$7.1B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
12%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
17%

See Also

What is Intellia Therapeutics Inc's Operating Income?
Operating Income
-892.7m USD

Based on the financial report for Mar 31, 2024, Intellia Therapeutics Inc's Operating Income amounts to -892.7m USD.

What is Intellia Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-57%

Over the last year, the Operating Income growth was -110%. The average annual Operating Income growth rates for Intellia Therapeutics Inc have been -81% over the past three years , -57% over the past five years .